Rapamycin Liposome Encapsulation for Bioavailability and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapamycin and its derivatives, known as rapalogs, suffer from low solubility and bioavailability, leading to limited clinical applications due to low oral bioavailability and high allergenicity of injectable forms, with no clinically available formulations offering high efficacy and low toxicity.
Innovation Solution
Development of a liposome formulation encapsulating rapamycin or its analogs, using specific lipid ingredients and cryoprotectants, which provides stability before and after lyophilization, and enhances tumor inhibition while reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If rapamycin is administered in conventional formulations, then the drug can be delivered to patients, but the bioavailability is low (14-18%) due to low aqueous solubility
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver rapamycin. The liposomal structure with specific lipid composition (HSPC, cholesterol, PEG-lipid) acts as a mediator that solubilizes the hydrophobic rapamycin in aqueous environments while maintaining drug stability and enabling controlled release, thereby dramatically improving bioavailability from 14-18% to superior levels.
Solution Approach 2:
The invention creates a composite liposomal formulation combining multiple lipid components (HSPC, cholesterol, PEG-lipid) with rapamycin. This composite material approach allows the formulation to simultaneously provide solubility enhancement, stability, and controlled release properties that neither the drug nor individual lipids could achieve alone.
2Quantity of substance
If injectable rapalog formulations are used to achieve high bioavailability, then bioavailability improves, but allergenicity increases due to excipients
Solution Approach 1:
The patent modifies the formulation parameters by using a specific liposomal composition with HSPC, cholesterol, and PEG-lipid in optimized ratios. This parameter optimization achieves high bioavailability while the biocompatible liposomal structure reduces allergenicity compared to conventional injectable excipients.
3Productivity
If conventional rapamycin formulations are used, then treatment can proceed, but toxicity is high limiting the maximum tolerated dose
Solution Approach 1:
The liposomal formulation segments the drug delivery system into a carrier (liposome) and payload (rapamycin). This segmentation allows the liposome to protect normal tissues from direct drug exposure while targeting tumor tissues, thereby reducing systemic toxicity and enabling higher maximum tolerated doses.
Solution Approach 2:
The patent implements local quality by designing the liposomal formulation to selectively accumulate in tumor tissues through the EPR effect and active targeting mechanisms. This creates high drug concentration at the tumor site (local) while maintaining low concentration in healthy tissues, thereby reducing overall toxicity and increasing the maximum tolerated dose.
4Ease of operation
If oral rapalog formulations are used, then administration is convenient, but bioavailability remains low due to poor solubility
Solution Approach 1:
The liposomal formulation acts as an intermediary carrier that enables oral administration of rapamycin by solubilizing the hydrophobic drug in the aqueous environment of the gastrointestinal tract. The liposomal structure protects the drug during digestion and facilitates absorption, making oral administration feasible with improved bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposome formulation achieves high bioavailability, superior tumor inhibition, and reduced toxicity, with a significantly higher maximum tolerated dose compared to previous formulations, demonstrating efficacy in cancer treatment with lower side effects.
Implementation Method 1
a lipid-based formulation comprising rapamycin and derivatives thereof
Implementation Method 2
having good stability before or after lyophilization and hydration
Data Source
AI summary
The present disclosure relates to a lipid-based formulation comprising rapamycin and derivatives thereof, and also relates to using the formulation for treatment of diseases or conditions, such as cancers, immuo-related disease, etc.